Detection and monitoring of cardiotoxicity—what does modern cardiology offer?

[1]  J. Voigt,et al.  Radiotherapy effects on systolic myocardial function detected by strain rate imaging in a left-breast cancer patient. , 2007, European heart journal.

[2]  G. Sutherland,et al.  Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients. , 2007, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[3]  N. Ayres,et al.  Evaluation of longitudinal ventricular function with tissue Doppler echocardiography in children treated with anthracyclines. , 2007, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[4]  Piet Claus,et al.  Acute cardiac functional and morphological changes after Anthracycline infusions in children. , 2007, The American journal of cardiology.

[5]  S. Achenbach,et al.  Current Role of Cardiac Computed Tomography , 2007, Herz Kardiovaskuläre Erkrankungen.

[6]  H. Caron,et al.  Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. , 2006, European journal of cancer.

[7]  H. Caron,et al.  Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. , 2006, European journal of cancer.

[8]  A. Weyman,et al.  Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury. , 2006, European heart journal.

[9]  G. Martinelli,et al.  Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity. , 2006, International journal of cardiology.

[10]  Katherine C. Wu,et al.  Delayed enhancement MR imaging: utility in myocardial assessment. , 2006, Radiographics : a review publication of the Radiological Society of North America, Inc.

[11]  L. Lagae,et al.  In utero exposure to chemotherapy: effect on cardiac and neurologic outcome. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Elaerts,et al.  Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. , 2006, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[13]  N. Better,et al.  Anticancer agents and cardiotoxicity. , 2006, Seminars in oncology.

[14]  J. Michálek,et al.  Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up , 2006, Supportive Care in Cancer.

[15]  Harald Becher,et al.  Analysis of regional left ventricular function by cineventriculography, cardiac magnetic resonance imaging, and unenhanced and contrast-enhanced echocardiography: a multicenter comparison of methods. , 2006, Journal of the American College of Cardiology.

[16]  R. Collins,et al.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[17]  V. Valero,et al.  Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Lipshultz,et al.  Pathophysiology of anthracycline‐ and radiation‐associated cardiomyopathies: Implications for screening and prevention , 2005, Pediatric blood & cancer.

[19]  J. Sandstede,et al.  The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. , 2005, European heart journal.

[20]  S. Lipsitz,et al.  Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  G. Martinelli,et al.  Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy , 2004, Circulation.

[22]  T. Suter,et al.  Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. , 2004, Breast.

[23]  B. Hesse,et al.  Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction , 2004, European journal of heart failure.

[24]  Jeroen J. Bax,et al.  Repetitive dobutamine stress echocardiography for the prediction of anthracycline cardiotoxicity. , 2003, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[25]  Oliver Turschner,et al.  Improvement of Cardiac Function During Enzyme Replacement Therapy in Patients With Fabry Disease: A Prospective Strain Rate Imaging Study , 2003, Circulation.

[26]  S. Takata,et al.  Ultrasonic analysis of anthracycline-induced myocardial damage using cyclic variation of integrated backscatter. , 2003, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[27]  M. Quiñones,et al.  Tissue Doppler Imaging Predicts the Development of Hypertrophic Cardiomyopathy in Subjects With Subclinical Disease , 2003, Circulation.

[28]  M. Drazner,et al.  B-type natriuretic peptide in cardiovascular disease , 2003, The Lancet.

[29]  S. Swain,et al.  Congestive heart failure in patients treated with doxorubicin , 2003, Cancer.

[30]  G. Sutherland,et al.  Idebenone treatment in Friedreich’s ataxia , 2003, Neurology.

[31]  M. Russo,et al.  Early Detection of Fabry Cardiomyopathy by Tissue Doppler Imaging , 2003, Circulation.

[32]  C. Kondo,et al.  Measurement of left ventricular volumes and ejection fraction by quantitative gated SPET, contrast ventriculography and magnetic resonance imaging: a meta-analysis , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  Thomas A Trikalinos,et al.  Electrocardiogram-gated single-photon emission computed tomography versus cardiac magnetic resonance imaging for the assessment of left ventricular volumes and ejection fraction: a meta-analysis. , 2002, Journal of the American College of Cardiology.

[34]  C. Hudis,et al.  Cardiac dysfunction in the trastuzumab clinical trials experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Thijssen,et al.  Discriminative ability of conventional echocardiography and tissue Doppler imaging techniques for the detection of subclinical cardiotoxic effects of treatment with anthracyclines. , 2001, Ultrasound in medicine & biology.

[36]  G R Sutherland,et al.  Can natural strain and strain rate quantify regional myocardial deformation? A study in healthy subjects. , 2001, Ultrasound in medicine & biology.

[37]  J. Schulz-Menger,et al.  Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study. , 2001, American heart journal.

[38]  S N Chatziioannou,et al.  Overestimation of the LVEF by quantitative gated SPECT in simulated left ventricles. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  G. Batist,et al.  Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Shinobu Nakamura,et al.  Brain Natriuretic Peptide Is a Predictor of Anthracycline-Induced Cardiotoxicity , 2001, Acta Haematologica.

[41]  O. Simonetti,et al.  The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. , 2000, The New England journal of medicine.

[42]  H. Torp,et al.  Myocardial Strain by Doppler Echocardiography: Validation of a New Method to Quantify Regional Myocardial Function , 2000, Circulation.

[43]  J. Thijssen,et al.  Tissue Doppler imaging in detection of myocardial dysfunction in survivors of childhood cancer treated with anthracyclines. , 2000, Ultrasound in medicine & biology.

[44]  P Suetens,et al.  Regional strain and strain rate measurements by cardiac ultrasound: principles, implementation and limitations. , 2000, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[45]  C. Klersy,et al.  Lack of clinically significant cardiac dysfunction during intermediate dobutamine doses in long-term childhood cancer survivors exposed to anthracyclines. , 2000, American heart journal.

[46]  G R Sutherland,et al.  Assessment of regional longitudinal myocardial strain rate derived from doppler myocardial imaging indexes in normal and infarcted myocardium. , 2000, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[47]  M. Nahata,et al.  Cardiotoxicity of Chemotherapeutic Agents , 2000 .

[48]  IkuoHashimoto,et al.  Automatic Border Detection Identifies Subclinical Anthracycline Cardiotoxicity in Children With Malignancy , 1999 .

[49]  P. Singal,et al.  Doxorubicin-induced cardiomyopathy. , 1998, The New England journal of medicine.

[50]  S. Lipsitz,et al.  Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. , 1997, Circulation.

[51]  S. Swain,et al.  Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  C. Angermann,et al.  Recognition of acute cardiac allograft rejection from serial integrated backscatter analyses in human orthotopic heart transplant recipients. Comparison with conventional echocardiography. , 1997, Circulation.

[53]  P. Rahko,et al.  The clinical utility of automatic boundary detection for the determination of left ventricular volume: a comparison with conventional off-line echocardiographic quantification. , 1995, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[54]  L Landini,et al.  Increased echodensity of myocardial wall in the diabetic heart: an ultrasound tissue characterization study. , 1995, Journal of the American College of Cardiology.

[55]  A. Keren,et al.  Findings of automatic border detection in subjects with left ventricular diastolic dysfunction by Doppler echocardiography. , 1995, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[56]  S. Colan,et al.  Monitoring for anthracycline cardiotoxicity. , 1994, Pediatrics.

[57]  R. Schwartz,et al.  Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. , 1992, Pediatrics.

[58]  L. Landini,et al.  Quantitative assessment of ultrasonic myocardial reflectivity in hypertrophic cardiomyopathy. , 1991, Journal of the American College of Cardiology.

[59]  David C Christiani,et al.  THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.

[60]  G. Bonadonna,et al.  Cardiac toxicity of daunorubicin. , 1969, Lancet.

[61]  M. Nahata,et al.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. , 2000, Drug safety.

[62]  M. Adamcová,et al.  Anthracycline-induced cardiotoxicity. , 2000, Acta medica.

[63]  M. Billingham,et al.  Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals. , 1978, JAMA.